A Single Arm, Open-label, Multicenter, Multinational, Safety and Efficacy Phase IIIb Trial of BI 695502 Plus mFOLFOX6 in Patients With Previously Untreated Metastatic Colorectal Cancer
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 04 Dec 2017
At a glance
- Drugs Bevacizumab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Colorectal cancer
- Focus Adverse reactions; Registrational
- Acronyms INVICTAN-3
- Sponsors Boehringer Ingelheim
- 05 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 26 Jun 2017 Planned End Date changed from 6 Dec 2018 to 7 Jan 2019.
- 26 Jun 2017 Planned primary completion date changed from 6 Dec 2018 to 7 Jan 2019.